| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0729de969d144562f56507e12fe00c64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0939f792bbd6b17d56fe1525826d37d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3ebb44cc10cb20b183a37750e1dcfac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14b1f495c397b02e4e93c39e7301c4ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50b58c181fd68ebda459271384ac03e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e90039aa1bba58bdb469b863ea9a7da1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2005-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2321df9566cd8514badcf3bcf0b752dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64e9fffe2b4cd1529c1d2993d6822f59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7715fa9fc425a4511e600c103f75724c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5827d18600acc52d9658f0971ac2583d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c519d78aee91130c5ebdc80672a4a8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71fd964c5032ded7089acf2184055fbb |
| publicationDate |
2006-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006076153-A2 |
| titleOfInvention |
Inherited mitochondrial dna mutations in cancer |
| abstract |
A method is provided for identifying a subject likely to have, or at risk of developing a disease condition correlated with increased reactive oxygen species (ROS), including cancer, by identifying in the subject a missense mutation in a nucleic acid of Complex III, IV and/or V of the OXPHOS system. This invention also provides a method of identifying a likelihood of having a heritable predisposition to cancer by detecting a homoplasmic missense mutation in non-tumor tissue of an OXPHOS system gene. This invention also provides a method for detecting likelihood of having cancer, predisposition to cancer, and likelihood of passing a predisposition to cancer to progeny involving identifying in non-tumor tissue of the subject a missense mutation in a complex III, IV and/or V gene of the mitochondrial OXPHOS system. The mutation may be a nuclear or mitochondrial mutation. The invention has been exemplified with respect to prostate cancer. When the mutation is homoplasmic in non-tumor tissue this is an indication it is an inherited and inheritable trait, and that the subject is likely to pass on the mutation to her progeny in the case of mutations in mitochondrial DNA or his or her progeny in the case of mutations in nuclear DNA. Both homoplasmic and heteroplasmic mutations in non-tumor tissue can indicate the presence of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008106701-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008106701-A2 |
| priorityDate |
2005-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |